Evaxion Biotech AS (EVAX) - Total Liabilities
Based on the latest financial reports, Evaxion Biotech AS (EVAX) has total liabilities worth $11.37 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Evaxion Biotech AS - Total Liabilities Trend (2017–2025)
This chart illustrates how Evaxion Biotech AS's total liabilities have evolved over time, based on quarterly financial data. See Evaxion Biotech AS current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Evaxion Biotech AS Competitors by Total Liabilities
The table below lists competitors of Evaxion Biotech AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OPCOM Holdings Bhd
KLSE:0035
|
Malaysia | RM106.72 Million |
|
G11 Resources Ltd
AU:G11
|
Australia | AU$161.95K |
|
BonTerra Resources Inc
V:BTR
|
Canada | CA$33.33 Million |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM11.72 Million |
|
TWay Holdings
KO:004870
|
Korea | ₩30.99 Billion |
|
ContextVision AB
OL:CONTX
|
Norway | Nkr35.12 Million |
|
WIIK Public Company Limited
BK:WIIK
|
Thailand | ฿833.60 Million |
|
Dayou AP Co.Ltd
KQ:290120
|
Korea | ₩201.77 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Evaxion Biotech AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Evaxion Biotech AS stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evaxion Biotech AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evaxion Biotech AS (2017–2025)
The table below shows the annual total liabilities of Evaxion Biotech AS from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.37 Million | -19.58% |
| 2024-12-31 | $14.14 Million | -19.76% |
| 2023-12-31 | $17.62 Million | +28.39% |
| 2022-12-31 | $13.72 Million | +77.61% |
| 2021-12-31 | $7.73 Million | +56.81% |
| 2020-12-31 | $4.93 Million | +186.12% |
| 2019-12-31 | $1.72 Million | -81.77% |
| 2018-12-31 | $9.44 Million | +2266.92% |
| 2017-12-31 | $399.00K | -- |
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid le… Read more